Quick Facts
| Legal Status | Medical Since | Adult Use | Access Type | Est. Monthly Cost | Insurance |
|---|---|---|---|---|---|
| Medical Experiment (2021–ongoing) | 2021 (pilot programme) | No | Specialist prescription — pilot pharmacies only | €200–€500/month | No (pilot phase) |
Legal Timeline
| Year | Development |
|---|---|
| 2013 | Sativex approved for MS but never reimbursed; extremely limited access |
| 2019 | ANSM (national medicines authority) begins review of medical cannabis access |
| 2021 | March: 4-year medical cannabis experiment launches with 3,000 patients |
| 2022 | Pilot expanded to over 2,500 authorised healthcare settings |
| 2023 | Patient enrolment reaches 15,000+ across France |
| 2024 | ANSM evaluates results; debate on permanent programme framework |
How to Access Medical Cannabis in France
- Your specialist (oncologist, neurologist, pain specialist) must be registered with the ANSM pilot programme
- Specialist evaluates your condition — only defined conditions qualify during the pilot phase
- Specialist initiates your enrolment in the programme (ANSM tracking system)
- Prescription valid for 3 months; dispensed by an authorised pilot pharmacy
- Products include dried flower (for vaporisation only — not smoking), oil, and capsules
- Regular follow-up mandatory; data collected for ongoing programme evaluation
Qualifying Conditions
- Neuropathic pain (refractory)
- Chemotherapy-related nausea and vomiting
- Spasticity linked to MS or brain/spinal cord injury
- Drug-resistant epilepsy
- Palliative care and pain management
Licensed Providers & Clinics
| Provider | Website | Notes |
|---|---|---|
| ANSM | ansm.sante.fr | Agence Nationale de Sécurité du Médicament — regulates and oversees the pilot |
| IQVIA France | Data partner for the pilot programme evaluation | |
| Tilray / IMC | International suppliers of pilot programme products |
Cost Breakdown
| Item | Estimated Cost (€) | Insurance Coverage |
|---|---|---|
| Dried flower (5g) | €40–€60 | Not reimbursed during pilot |
| Oil / capsules (30 days) | €100–€200 | Not reimbursed during pilot |
| Specialist consultation | €50–€150 | Covered by Assurance Maladie |
Frequently Asked Questions
Is medical cannabis legal in France?+
France is running a 4-year medical cannabis pilot experiment that began in March 2021. During the pilot, eligible patients can access standardised cannabis products via authorised specialist doctors and pharmacies. It is legal within the pilot framework, but not yet a permanent programme.
Who can access the French medical cannabis pilot?+
Patients with refractory neuropathic pain, chemotherapy-related nausea, MS spasticity, drug-resistant epilepsy, or palliative care needs may qualify. Access is through a registered specialist doctor — not a GP — who is enrolled in the ANSM programme.
Is medical cannabis reimbursed in France?+
No — the pilot programme explicitly excludes reimbursement by Assurance Maladie (the French state health insurer). Patients pay full costs out of pocket for cannabis products, though the specialist consultations themselves may be covered.
Can I vaporise cannabis medically in France?+
Dried flower products dispensed in the French pilot are approved for vaporisation only — not smoking. Vaporisers are not officially provided but patients are expected to use a medical-grade device.
What happens after the pilot ends?+
ANSM is evaluating the pilot data on safety, efficacy, and access equity. A decision on permanent medical cannabis legalisation in France is expected based on these results. The timeline for any permanent programme depends on legislative action.
Can tourists access medical cannabis in France?+
No. The pilot is only available to French residents enrolled through ANSM-registered specialists. Tourists cannot access the programme.